The use of otic powder in the treatment of acute external otitis

Background: Acute external otitis (AEO) is a painful condition that results as a secondary infection of macerated skin and subcutaneous tissues of the external auditory canal. The most commonly causative microorganisms are Pseudomonas aeruginosa and Staphylococcus aureus. Classic management strategi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of otolaryngology 2002-05, Vol.23 (3), p.142-147
Hauptverfasser: Goldenberg, David, Golz, Avishay, Netzer, Aviram, Joachims, Henry Zvi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 147
container_issue 3
container_start_page 142
container_title American journal of otolaryngology
container_volume 23
creator Goldenberg, David
Golz, Avishay
Netzer, Aviram
Joachims, Henry Zvi
description Background: Acute external otitis (AEO) is a painful condition that results as a secondary infection of macerated skin and subcutaneous tissues of the external auditory canal. The most commonly causative microorganisms are Pseudomonas aeruginosa and Staphylococcus aureus. Classic management strategies include moisture prevention, cleansing of the canal and administration of topical antimicrobial agents in drop form, such as aminoglycosides and quinolones, at times in combination with steroid solutions. The objective of this study was to evaluate and compare the efficacy of topical otic powder, tobramycin drops and ciprofloxacin drops in patients suffering from AEO. Materials and Measures: A randomized prospective trial was performed to determine the efficacy of Auricularum powder (dexamethasone 10 mg, oxytetracycline HCl 90,000 U, polymyxin B Sulfate 100,000 U, nystatin 1,000,000 U; Trima, Serolam Laboratories, Germany) compared with ciprofloxacin (Ciloxan, Alcon Laboratories, Fort Worth, TX) and tobramycin (Tobrex, Alcon Laboratories) drops for the treatment of AEO. One hundred twenty patients who presented with signs and symptoms of AEO were enrolled. Inclusion criteria were: AEO diagnosed by an otolaryngologist, patient age 18 years, no prior treatment with other drops or systemic antibiotics, no sensitivity to any of the drugs used or their contents, and no perforation of the tympanic membrane. All patients were instructed to avoid moisture and wetness of the ear during the course of their treatment. After we received informed consent, a swab culture was taken, and the patient was randomly assigned topical treatment for 14 days. Results: Eighty-six percent of those treated with Auricularum powder were cured at day 3-4 after initial treatment. Seventy-seven percent of those treated with ciprofloxacin drops, and fifty-six percent of those treated with tobramycin were cured at that time. All 120 patients were cured by day 14. Conclusion: The results show that topical treatment with Auricularum powder is an effective and rapid method for the treatment of AEO. Ciloxan also was effective in the treatment of AEO and relieved symptoms quickly and efficiently in a short period of time. Tobrex was effective in treating AEO, but our results show that relief of symptoms was slower than with the other drugs. (Am J Otolaryngol 2002;23:142-147. Copyright 2002, Elsevier Science (USA). All rights reserved.)
doi_str_mv 10.1053/ajot.2002.123461
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71703168</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S019607090262513X</els_id><sourcerecordid>71703168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-4da923e7fa66a8611bd107607e3e41eef8dbba6e477d215f58352eaa052383033</originalsourceid><addsrcrecordid>eNp1kDtPwzAUhS0EoqWwM6EssKVc24mdMoEqXlIlliKxWY5zI1zlUWyHx78nUSIxMd3hfOfo6iPknMKSQsqv9a4NSwbAlpTxRNADMqcpZ3FGs7dDMge6EjFIWM3Iifc7AOAJT4_JjLI-SjI2J7fbd4w6j1FbRm2wJtq3XwW6yDZR6JPgUIcamzDk2nQBI_wO6BpdDXiw_pQclbryeDbdBXl9uN-un-LNy-Pz-m4TGy5FiJNCrxhHWWohdCYozQsKUoBEjglFLLMiz7XARMqC0bRMM54y1BpSxjMOnC_I1bi7d-1Hhz6o2nqDVaUbbDuvJJXAqch6EEbQuNZ7h6XaO1tr96MoqMGaGqypwZoarfWVi2m7y2ss_gqTph64nADtja5Kpxtj_R_HhUj7R3vuZuSwN_Fp0SlvLDYGC-vQBFW09v8vfgHVKIgG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71703168</pqid></control><display><type>article</type><title>The use of otic powder in the treatment of acute external otitis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Goldenberg, David ; Golz, Avishay ; Netzer, Aviram ; Joachims, Henry Zvi</creator><creatorcontrib>Goldenberg, David ; Golz, Avishay ; Netzer, Aviram ; Joachims, Henry Zvi</creatorcontrib><description>Background: Acute external otitis (AEO) is a painful condition that results as a secondary infection of macerated skin and subcutaneous tissues of the external auditory canal. The most commonly causative microorganisms are Pseudomonas aeruginosa and Staphylococcus aureus. Classic management strategies include moisture prevention, cleansing of the canal and administration of topical antimicrobial agents in drop form, such as aminoglycosides and quinolones, at times in combination with steroid solutions. The objective of this study was to evaluate and compare the efficacy of topical otic powder, tobramycin drops and ciprofloxacin drops in patients suffering from AEO. Materials and Measures: A randomized prospective trial was performed to determine the efficacy of Auricularum powder (dexamethasone 10 mg, oxytetracycline HCl 90,000 U, polymyxin B Sulfate 100,000 U, nystatin 1,000,000 U; Trima, Serolam Laboratories, Germany) compared with ciprofloxacin (Ciloxan, Alcon Laboratories, Fort Worth, TX) and tobramycin (Tobrex, Alcon Laboratories) drops for the treatment of AEO. One hundred twenty patients who presented with signs and symptoms of AEO were enrolled. Inclusion criteria were: AEO diagnosed by an otolaryngologist, patient age 18 years, no prior treatment with other drops or systemic antibiotics, no sensitivity to any of the drugs used or their contents, and no perforation of the tympanic membrane. All patients were instructed to avoid moisture and wetness of the ear during the course of their treatment. After we received informed consent, a swab culture was taken, and the patient was randomly assigned topical treatment for 14 days. Results: Eighty-six percent of those treated with Auricularum powder were cured at day 3-4 after initial treatment. Seventy-seven percent of those treated with ciprofloxacin drops, and fifty-six percent of those treated with tobramycin were cured at that time. All 120 patients were cured by day 14. Conclusion: The results show that topical treatment with Auricularum powder is an effective and rapid method for the treatment of AEO. Ciloxan also was effective in the treatment of AEO and relieved symptoms quickly and efficiently in a short period of time. Tobrex was effective in treating AEO, but our results show that relief of symptoms was slower than with the other drugs. (Am J Otolaryngol 2002;23:142-147. Copyright 2002, Elsevier Science (USA). All rights reserved.)</description><identifier>ISSN: 0196-0709</identifier><identifier>EISSN: 1532-818X</identifier><identifier>DOI: 10.1053/ajot.2002.123461</identifier><identifier>PMID: 12019482</identifier><identifier>CODEN: AJOTDP</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Acute Disease ; Adolescent ; Adult ; Anti-Bacterial Agents - therapeutic use ; Anti-Infective Agents - therapeutic use ; Biological and medical sciences ; Ciprofloxacin - therapeutic use ; Dexamethasone - analogs &amp; derivatives ; Dexamethasone - therapeutic use ; Drug Combinations ; Ear, auditive nerve, cochleovestibular tract, facial nerve: diseases, semeiology ; Ent. Stomatology ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Non tumoral diseases ; Nystatin - therapeutic use ; Otitis Externa - drug therapy ; Otorhinolaryngology. Stomatology ; Oxytetracycline - therapeutic use ; Pharmacology. Drug treatments ; Polymyxin B - therapeutic use ; Powders - therapeutic use ; Prospective Studies ; Tobramycin - therapeutic use ; Tropical medicine</subject><ispartof>American journal of otolaryngology, 2002-05, Vol.23 (3), p.142-147</ispartof><rights>2002 Elsevier Science (USA)</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2002, Elsevier Science (USA). All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-4da923e7fa66a8611bd107607e3e41eef8dbba6e477d215f58352eaa052383033</citedby><cites>FETCH-LOGICAL-c376t-4da923e7fa66a8611bd107607e3e41eef8dbba6e477d215f58352eaa052383033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/ajot.2002.123461$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13665523$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12019482$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldenberg, David</creatorcontrib><creatorcontrib>Golz, Avishay</creatorcontrib><creatorcontrib>Netzer, Aviram</creatorcontrib><creatorcontrib>Joachims, Henry Zvi</creatorcontrib><title>The use of otic powder in the treatment of acute external otitis</title><title>American journal of otolaryngology</title><addtitle>Am J Otolaryngol</addtitle><description>Background: Acute external otitis (AEO) is a painful condition that results as a secondary infection of macerated skin and subcutaneous tissues of the external auditory canal. The most commonly causative microorganisms are Pseudomonas aeruginosa and Staphylococcus aureus. Classic management strategies include moisture prevention, cleansing of the canal and administration of topical antimicrobial agents in drop form, such as aminoglycosides and quinolones, at times in combination with steroid solutions. The objective of this study was to evaluate and compare the efficacy of topical otic powder, tobramycin drops and ciprofloxacin drops in patients suffering from AEO. Materials and Measures: A randomized prospective trial was performed to determine the efficacy of Auricularum powder (dexamethasone 10 mg, oxytetracycline HCl 90,000 U, polymyxin B Sulfate 100,000 U, nystatin 1,000,000 U; Trima, Serolam Laboratories, Germany) compared with ciprofloxacin (Ciloxan, Alcon Laboratories, Fort Worth, TX) and tobramycin (Tobrex, Alcon Laboratories) drops for the treatment of AEO. One hundred twenty patients who presented with signs and symptoms of AEO were enrolled. Inclusion criteria were: AEO diagnosed by an otolaryngologist, patient age 18 years, no prior treatment with other drops or systemic antibiotics, no sensitivity to any of the drugs used or their contents, and no perforation of the tympanic membrane. All patients were instructed to avoid moisture and wetness of the ear during the course of their treatment. After we received informed consent, a swab culture was taken, and the patient was randomly assigned topical treatment for 14 days. Results: Eighty-six percent of those treated with Auricularum powder were cured at day 3-4 after initial treatment. Seventy-seven percent of those treated with ciprofloxacin drops, and fifty-six percent of those treated with tobramycin were cured at that time. All 120 patients were cured by day 14. Conclusion: The results show that topical treatment with Auricularum powder is an effective and rapid method for the treatment of AEO. Ciloxan also was effective in the treatment of AEO and relieved symptoms quickly and efficiently in a short period of time. Tobrex was effective in treating AEO, but our results show that relief of symptoms was slower than with the other drugs. (Am J Otolaryngol 2002;23:142-147. Copyright 2002, Elsevier Science (USA). All rights reserved.)</description><subject>Acute Disease</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Dexamethasone - analogs &amp; derivatives</subject><subject>Dexamethasone - therapeutic use</subject><subject>Drug Combinations</subject><subject>Ear, auditive nerve, cochleovestibular tract, facial nerve: diseases, semeiology</subject><subject>Ent. Stomatology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Non tumoral diseases</subject><subject>Nystatin - therapeutic use</subject><subject>Otitis Externa - drug therapy</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Oxytetracycline - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymyxin B - therapeutic use</subject><subject>Powders - therapeutic use</subject><subject>Prospective Studies</subject><subject>Tobramycin - therapeutic use</subject><subject>Tropical medicine</subject><issn>0196-0709</issn><issn>1532-818X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kDtPwzAUhS0EoqWwM6EssKVc24mdMoEqXlIlliKxWY5zI1zlUWyHx78nUSIxMd3hfOfo6iPknMKSQsqv9a4NSwbAlpTxRNADMqcpZ3FGs7dDMge6EjFIWM3Iifc7AOAJT4_JjLI-SjI2J7fbd4w6j1FbRm2wJtq3XwW6yDZR6JPgUIcamzDk2nQBI_wO6BpdDXiw_pQclbryeDbdBXl9uN-un-LNy-Pz-m4TGy5FiJNCrxhHWWohdCYozQsKUoBEjglFLLMiz7XARMqC0bRMM54y1BpSxjMOnC_I1bi7d-1Hhz6o2nqDVaUbbDuvJJXAqch6EEbQuNZ7h6XaO1tr96MoqMGaGqypwZoarfWVi2m7y2ss_gqTph64nADtja5Kpxtj_R_HhUj7R3vuZuSwN_Fp0SlvLDYGC-vQBFW09v8vfgHVKIgG</recordid><startdate>20020501</startdate><enddate>20020501</enddate><creator>Goldenberg, David</creator><creator>Golz, Avishay</creator><creator>Netzer, Aviram</creator><creator>Joachims, Henry Zvi</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>8BM</scope></search><sort><creationdate>20020501</creationdate><title>The use of otic powder in the treatment of acute external otitis</title><author>Goldenberg, David ; Golz, Avishay ; Netzer, Aviram ; Joachims, Henry Zvi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-4da923e7fa66a8611bd107607e3e41eef8dbba6e477d215f58352eaa052383033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Acute Disease</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Dexamethasone - analogs &amp; derivatives</topic><topic>Dexamethasone - therapeutic use</topic><topic>Drug Combinations</topic><topic>Ear, auditive nerve, cochleovestibular tract, facial nerve: diseases, semeiology</topic><topic>Ent. Stomatology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Non tumoral diseases</topic><topic>Nystatin - therapeutic use</topic><topic>Otitis Externa - drug therapy</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Oxytetracycline - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymyxin B - therapeutic use</topic><topic>Powders - therapeutic use</topic><topic>Prospective Studies</topic><topic>Tobramycin - therapeutic use</topic><topic>Tropical medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldenberg, David</creatorcontrib><creatorcontrib>Golz, Avishay</creatorcontrib><creatorcontrib>Netzer, Aviram</creatorcontrib><creatorcontrib>Joachims, Henry Zvi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>ComDisDome</collection><jtitle>American journal of otolaryngology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldenberg, David</au><au>Golz, Avishay</au><au>Netzer, Aviram</au><au>Joachims, Henry Zvi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of otic powder in the treatment of acute external otitis</atitle><jtitle>American journal of otolaryngology</jtitle><addtitle>Am J Otolaryngol</addtitle><date>2002-05-01</date><risdate>2002</risdate><volume>23</volume><issue>3</issue><spage>142</spage><epage>147</epage><pages>142-147</pages><issn>0196-0709</issn><eissn>1532-818X</eissn><coden>AJOTDP</coden><abstract>Background: Acute external otitis (AEO) is a painful condition that results as a secondary infection of macerated skin and subcutaneous tissues of the external auditory canal. The most commonly causative microorganisms are Pseudomonas aeruginosa and Staphylococcus aureus. Classic management strategies include moisture prevention, cleansing of the canal and administration of topical antimicrobial agents in drop form, such as aminoglycosides and quinolones, at times in combination with steroid solutions. The objective of this study was to evaluate and compare the efficacy of topical otic powder, tobramycin drops and ciprofloxacin drops in patients suffering from AEO. Materials and Measures: A randomized prospective trial was performed to determine the efficacy of Auricularum powder (dexamethasone 10 mg, oxytetracycline HCl 90,000 U, polymyxin B Sulfate 100,000 U, nystatin 1,000,000 U; Trima, Serolam Laboratories, Germany) compared with ciprofloxacin (Ciloxan, Alcon Laboratories, Fort Worth, TX) and tobramycin (Tobrex, Alcon Laboratories) drops for the treatment of AEO. One hundred twenty patients who presented with signs and symptoms of AEO were enrolled. Inclusion criteria were: AEO diagnosed by an otolaryngologist, patient age 18 years, no prior treatment with other drops or systemic antibiotics, no sensitivity to any of the drugs used or their contents, and no perforation of the tympanic membrane. All patients were instructed to avoid moisture and wetness of the ear during the course of their treatment. After we received informed consent, a swab culture was taken, and the patient was randomly assigned topical treatment for 14 days. Results: Eighty-six percent of those treated with Auricularum powder were cured at day 3-4 after initial treatment. Seventy-seven percent of those treated with ciprofloxacin drops, and fifty-six percent of those treated with tobramycin were cured at that time. All 120 patients were cured by day 14. Conclusion: The results show that topical treatment with Auricularum powder is an effective and rapid method for the treatment of AEO. Ciloxan also was effective in the treatment of AEO and relieved symptoms quickly and efficiently in a short period of time. Tobrex was effective in treating AEO, but our results show that relief of symptoms was slower than with the other drugs. (Am J Otolaryngol 2002;23:142-147. Copyright 2002, Elsevier Science (USA). All rights reserved.)</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>12019482</pmid><doi>10.1053/ajot.2002.123461</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0196-0709
ispartof American journal of otolaryngology, 2002-05, Vol.23 (3), p.142-147
issn 0196-0709
1532-818X
language eng
recordid cdi_proquest_miscellaneous_71703168
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Acute Disease
Adolescent
Adult
Anti-Bacterial Agents - therapeutic use
Anti-Infective Agents - therapeutic use
Biological and medical sciences
Ciprofloxacin - therapeutic use
Dexamethasone - analogs & derivatives
Dexamethasone - therapeutic use
Drug Combinations
Ear, auditive nerve, cochleovestibular tract, facial nerve: diseases, semeiology
Ent. Stomatology
Female
Humans
Male
Medical sciences
Middle Aged
Non tumoral diseases
Nystatin - therapeutic use
Otitis Externa - drug therapy
Otorhinolaryngology. Stomatology
Oxytetracycline - therapeutic use
Pharmacology. Drug treatments
Polymyxin B - therapeutic use
Powders - therapeutic use
Prospective Studies
Tobramycin - therapeutic use
Tropical medicine
title The use of otic powder in the treatment of acute external otitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A12%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20otic%20powder%20in%20the%20treatment%20of%20acute%20external%20otitis&rft.jtitle=American%20journal%20of%20otolaryngology&rft.au=Goldenberg,%20David&rft.date=2002-05-01&rft.volume=23&rft.issue=3&rft.spage=142&rft.epage=147&rft.pages=142-147&rft.issn=0196-0709&rft.eissn=1532-818X&rft.coden=AJOTDP&rft_id=info:doi/10.1053/ajot.2002.123461&rft_dat=%3Cproquest_cross%3E71703168%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71703168&rft_id=info:pmid/12019482&rft_els_id=S019607090262513X&rfr_iscdi=true